GSK PLC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 4,638,049 | $179,678,018 | 0.60% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 4,556,621 | $174,974,246 | 0.57% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2025 |
| Sept. 30, 2025 | 4,602,201 | $198,630,995 | 0.61% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 14, 2025 |
| Dec. 31, 2025 | 3,657,931 | $179,384,936 | 0.54% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 3,482,054 | $192,174,560 | 0.59% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2026 |
| June 30, 2026 | 3,413,574 | $178,939,549 | 0.52% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.